The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Paliperidone Janssen 75 mg prolonged-release suspension for injection.



Janssen-Cilag International NVEU/1/14/971/003

Main Information

Trade NamePaliperidone Janssen 75 mg prolonged-release suspension for injection.
Active SubstancesPaliperidone palmitate (r092670)
Dosage FormProlonged-release suspension for injection
Licence HolderJanssen-Cilag International NV
Licence NumberEU/1/14/971/003

Group Information

ATC CodeN05A ANTIPSYCHOTICS

Status

License statusAuthorised
Licence Issued05/12/2014
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website

Generics Information

Interchangeable List CodeIC0130-028-064
Interchangeable List DocumentPDF of Interchangeable List
« Back